Background text container image for FUJIFILM homepage

Partners for Life

STATEMENT ON COVID-19

With employees, partners and operations across multiple geographies, FUJIFILM Diosynth Biotechnologies (“FDB”) is closely monitoring the evolving situation of COVID-19, along with the rest of the world.

25+ Years of Experience

What We Do

Formulation Development

Balancing the need for speed with robust science with comprehensive and modern analytical and formulation capabilities and technical expertise
Learn More

Saturn

A Monoclonal Antibody Platform for reliable delivery of mAb based therapeutics
Learn More

Apollo X Mammalian Expression

A Mammalian Expression Platform developed for robust, high levels of monoclonal antibody expression designed with manufacturability for the entire life of your product
Learn More

Paveway Microbial Expression

Incorporating key aspects for the delivery of an E.coli based expression process with industry leading titers and suitable for large-scale manufacture using antibiotic-free fermentation
Learn More

Gene Therapy

Delivering scalable Gene Therapy processes.
Learn More

Thought Leadership

You are about to embark on a clinical journey—be it early, pre-clinical investigation or a later phase of the product lifecycle—it’s good to know Thought Leaders are paving the way.
Learn More
Featured
press-releases
brochures
publications
case-study
whitepaper
Press Releases

Fujifilm Invests $83M USD to Expand FUJIFILM Diosynth Biotechnologies Microbial Capacity

The expansion will take place in its Billingham, UK site

Learn More
Press Releases

Christine Vannais is appointed as FDB’s North Carolina Site Chief Operating Officer

FDB is pleased to formally announce the appointment of Christine Vannais as Chief Operating Officer (COO) of its North Carolina site.

Learn More
Press Releases

This BioCampus development will include the construction of 42,000 square foot purpose built office

Learn More
Brochure

Apollo X Brochure

Learn more how we can optimize the cell line development process without compromising quality to reach titers up to 10 g/L in 10 weeks.

Learn More
Brochure

pAVEway Advanced Microbial Expression Platform

Learn more about our innovative microbial expression system for large-scale production of antibiotic-free therapeutic proteins.

Learn More
Brochure

Gene Therapies Brochure

Learn more about our Viral Products Expertise Experience & Capabilities

Learn More
Publications

Mass Spectrometric Conjugate Characterization: Process Qualification of Recombinant Protein–Hapten Conjugation

Here we present case studies in development of reliable methods based on mass spectrometry (MS) to characterize a protein–hapten drug substance during late-phase process validation. This protein is modified by succinylation to enable conjugation with an aminated hapten.

Learn More
Publications

Rapid Development of High-Quality, Robust Mammalian Cell Culture Manufacturing Processes

Learn the approach that our scientists uses to accelerate the development process from gene to finish by shortening the timeline, incorporating quality by design (QbD) principles, and designing the process to be as robust as possible.

Learn More
Case Study

Expanding Single-Use Biomanufacturing

There are key considerations to take into account when expanding with single-use biologics manufacturing. These technologies readily enable duplicate capacity.

Learn More
Case Study

Single-Use Biologics Manufacturing for Long Term Needs

CDMOs can ensure to meet demand with single-use biologics manufacturing technologies. We have 5 key considerations for securing your supply chain and future-proofing your organization.

Learn More
Case Study

Assessing Biologics Manufacturing Needs

When determining the right type of biomanufacturing capacity for your biologics manufacturing needs, there are key considerations to take into account.

Learn More
Whitepapers

Scale-Down Model Development in ambr systems: An Industrial Perspective

High-Throughput (HT) technologies such as miniature bioreactors (MBRs) are increasingly employed within the biopharmaceutical manufacturing industry. Traditionally, these technologies have been utilized for discrete screening approaches during pre-clinical development (e.g., cell line selection and process optimization).

Learn More
Whitepapers

Xtalks from gene to manufacturing

Application of efficient cell line development strategies to deliver reliable, high quality biomanufacturing processes

Learn More
Whitepapers

pAVEwayTM expression system for the efficient expression of therapeutic proteins

The Escherichia coli pAVEwayTM expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimizing many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).

Learn More